Virtual Library
Start Your Search
Yuwang Tian
Author of
-
+
P3.13 - Targeted Therapy (Not CME Accredited Session) (ID 979)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.13-06 - Analysis of ALK Rearrangement Non-Small Cell Lung Cancer Cell Blocks from Pleural Effusion (ID 11112)
12:00 - 13:30 | Author(s): Yuwang Tian
- Abstract
Background
Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non-small-cell lung cancers (NSCLCs). Crizotinib, an ALK inhibitor, has been demonstrated to provide dramatic clinical benefits in ALK rearrangement advanced NSCLC. The aim of this study is to investigate the clinical value of ALK rearrangement NSCLC blocks cell from pleural effusion.
a9ded1e5ce5d75814730bb4caaf49419 Method
Two hundred and fifteen cases of ALK rearrangement non-small cell lung cancer (NSCLC) blocks cell from pleural effusion, Four hundred and four cases of tissues were detected by reverse transcription polymerase chain reaction (RT-PCR) method. The consistency of ALK rearrangement was examined in 74 cases of patients with tissues and cell blocks.
4c3880bb027f159e801041b1021e88e8 Result
ALK rearrangement was found in 26 of 215 cell blocks (positive detection rate of 12.09 %). ALK rearrangement was detected in 25 of 404 tissue blocks (positive detection rate of 6.19%). There were 67 cases in the 74 (90.54%) cases had the same consistency as tissue block. ALK rearrangement was detected in 11 of 74 (14.86%) cell blocks, and 14 of 74 (18.92%) tissue blocks.
8eea62084ca7e541d918e823422bd82e Conclusion
The rate of ALK rearrangement in cell blocks of NSCLC is higher than in matched tissue blocks. The patients with malignant pleural effusion are likely to tend ALK rearrangement.
6f8b794f3246b0c1e1780bb4d4d5dc53